Tenax Therapeutics, formerly Oxygen Biotherapeutics, is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care patients. The Company's main product is levosimendan, which is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand.

Type
Public
HQ
Morrisville, US
Founded
1967
Size (employees)
10 (est)
Tenax Therapeutics was founded in 1967 and is headquartered in Morrisville, US
Report incorrect company information

Tenax Therapeutics Office Locations

Tenax Therapeutics has an office in Morrisville
Morrisville, US (HQ)
490 1 Copley Pkwy
Show all (1)
Report incorrect company information

Tenax Therapeutics Financials and Metrics

Tenax Therapeutics Financials

USD

Net income (Q1, 2018)

1.2 m

Market capitalization (21-May-2018)

8.5 m

Closing share price (21-May-2018)

5.8

Cash (31-Mar-2018)

3 m
Tenax Therapeutics's current market capitalization is $8.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

158.9 k49.3 k

Revenue growth, %

(69%)(100%)

Cost of goods sold

Gross profit

Quarterly
USDQ1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

1.4 m1.2 m1.8 m1.2 m1.3 m1.4 m1.8 m1.2 m

R&D expense

1.7 m2.5 m3.9 m3.4 m3.2 m2.1 m1.2 m58.6 k

Operating expense total

3.1 m3.7 m5.7 m4.7 m4.5 m3.5 m3 m1.2 m

Interest expense

1.1 k404
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

58.3 m7.9 m10 m

Accounts Receivable

36.4 k76.5 k72.6 k

Current Assets

59 m17.5 m13.6 m

PP&E

124.4 k50.3 k19.1 k
Quarterly
USDQ1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

3.7 m5.1 m3.3 m1.9 m722.2 k7 m2.2 m3 m

Accounts Receivable

98.6 k86.3 k49.3 k24.6 k72.6 k24.6 k24.6 k39.3 k

Current Assets

21.6 m21.9 m16.1 m10.2 m7.7 m12.8 m9 m7 m

PP&E

54.4 k42.1 k34 k29 k23.5 k18.3 k14.9 k10.5 k
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(19.5 m)(14.1 m)(10.1 m)

Depreciation and Amortization

150.5 k148.1 k31.2 k

Inventories

Cash From Operating Activities

(9.3 m)(9.7 m)(9 m)
Quarterly
USDQ1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(3 m)(6.6 m)(5.4 m)(10 m)(14.3 m)(3.3 m)6.3 m(1.2 m)

Depreciation and Amortization

12.7 k25 k4.6 k9.7 k14.5 k4 k7.5 k2.6 k

Accounts Payable

(684.8 k)

Cash From Operating Activities

(3.8 m)(6.5 m)(3.3 m)(8.5 m)(12.8 m)(4 m)(9.6 m)(1.6 m)
USDY, 2018

Financial Leverage

1 x
Show all financial metrics

Tenax Therapeutics Operating Metrics

FY, 2016

Patents Issued

7

Phase III Trials Products

1

Preclinical Phase Products

1
Show all operating metrics
Report incorrect company information